<DOC>
	<DOCNO>NCT01187992</DOCNO>
	<brief_summary>This study design test hypothesis addition full-dose atorvastatin ( 80 mg/day ) conventional medical treatment could reduce ischaemic recurrence non-ST-elevation acute myocardial infarction ( NSTE-AMI ) patient severe diffuse coronary artery disease ( CAD ) amenable form mechanical revascularisation .</brief_summary>
	<brief_title>Full-dose Atorvastatin After Acute Coronary Syndrome ( ACS ) Non-revascularisable Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>nonSTsegment elevation acute myocardial infarction . coronary angiography within 48 hour admission . angiographic evidence severe diffuse coronary artery disease , amenable conventional direct revascularisation technique coronary artery bypass graft ( CABG ) percutaneous coronary intervention ( PCI ) . STsegment elevation acute myocardial infarction , clinical history heart failure leave ventricular ejection fraction &lt; 35 % , form severe valvular dysfunction , previous implantation indication implant cardioverterdefibrillator index admission , increase liver enzymes , history liver muscle disease , renal failure serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) , need continue use intravenous medication relieve anginal symptom , presence major comorbidity life expectancy &lt; 24 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Advanced coronary artery disease</keyword>
</DOC>